

James D Chambers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/333229/publications.pdf>

Version: 2024-02-01

54
papers

947
citations

394421

19
h-index

477307

29
g-index

55
all docs

55
docs citations

55
times ranked

1042
citing authors

#	ARTICLE	IF	CITATIONS
1	Is an Orphan Drug's Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?. <i>Pharmacoeconomics</i> , 2022, 40, 225-232.	3.3	6
2	Are Medical Devices Cost-Effective?. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 235-241.	2.1	1
3	Patients' access to rare neuromuscular disease therapies varies across US private insurers. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 36.	2.7	11
4	An Evidence Review of Low-Value Care Recommendations: Inconsistency and Lack of Economic Evidence Considered. <i>Journal of General Internal Medicine</i> , 2021, 36, 3448-3455.	2.6	12
5	Limited role of patient input in specialty drug coverage policies. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1067-1076.	0.9	0
6	Variation in access to hemophilia A treatments in the United States. <i>Journal of Medical Economics</i> , 2021, 24, 1143-1148.	2.1	0
7	Variation in health plan coverage of ESAs for anemia due to chronic kidney disease. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1221-1229.	0.9	0
8	Variation in market access decisions for cell and gene therapies across the United States, Canada, and Europe. <i>Health Policy</i> , 2021, 125, 1550-1556.	3.0	11
9	Variation In Use And Content Of Prescription Drug Step Therapy Protocols, Within And Across Health Plans. <i>Health Affairs</i> , 2021, 40, 1749-1757.	5.2	10
10	Use of prescriber requirements among US commercial health plans. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1757-1762.	0.9	3
11	Coverage for Biosimilars vs Reference Products Among US Commercial Health Plans. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1972.	7.4	20
12	What types of real-world evidence studies do U.S. commercial health plans cite in their specialty drug coverage decisions?. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1307-1311.	1.9	5
13	Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs. <i>Journal of General Internal Medicine</i> , 2020, 35, 2629-2636.	2.6	29
14	Little Consistency In Evidence Cited By Commercial Plans For Specialty Drug Coverage. <i>Health Affairs</i> , 2019, 38, 1882-1886.	5.2	13
15	Variation in US private health plans' coverage of orphan drugs. <i>American Journal of Managed Care</i> , 2019, 25, 508-512.	1.1	14
16	Insurance coverage for genomic tests. <i>Science</i> , 2018, 360, 278-279.	12.6	18
17	A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical Procedures. <i>Value in Health</i> , 2018, 21, 400-406.	0.3	4
18	Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 1240-1246.	0.9	4

#	ARTICLE	IF	CITATIONS
19	Specialty Drug Coverage Varies Across Commercial Health Plans In The US. Health Affairs, 2018, 37, 1041-1047.	5.2	45
20	Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 632-642.	0.9	35
21	Estimating Population Health Benefits Associated with Specialty and Traditional Drugs in the Year Following Product Approval. Applied Health Economics and Health Policy, 2017, 15, 227-235.	2.1	1
22	The influence of time horizon on results of cost-effectiveness analyses. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 615-623.	1.4	51
23	The Decline in Vitamin Research Funding: A Missed Opportunity?. Current Developments in Nutrition, 2017, 1, e000430.	0.3	4
24	A Review of Empirical Analyses of Disinvestment Initiatives. Value in Health, 2017, 20, 909-918.	0.3	29
25	EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS. International Journal of Technology Assessment in Health Care, 2017, 33, 534-540.	0.5	20
26	Drugs Cleared Through The FDA's Expedited Review Offer Greater Gains Than Drugs Approved By Conventional Process. Health Affairs, 2017, 36, 1408-1415.	5.2	20
27	Variation in Private Payer Coverage of Rheumatoid Arthritis Drugs. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 1176-1181.	0.9	9
28	The Role of Decision Models in Health Care Policy. Medical Decision Making, 2016, 36, 666-679.	2.4	2
29	Thirty Years of Media Coverage on High Drug Prices in the United States—A Never-Ending Story or a Time for Change?. Value in Health, 2016, 19, 14-16.	0.3	6
30	Docetaxel chemotherapy in metastatic castration-resistant prostate cancer (mCRPC): Cost of care for Medicare and commercially insured men.. Journal of Clinical Oncology, 2016, 34, 262-262.	1.6	0
31	The impact of formulary drug exclusion policies on patients and healthcare costs. American Journal of Managed Care, 2016, 22, 524-31.	1.1	7
32	Mapping US commercial payers' coverage policies for medical interventions. American Journal of Managed Care, 2016, 22, e323-8.	1.1	5
33	CHANGING FACE OF MEDICARE'S NATIONAL COVERAGE DETERMINATIONS FOR TECHNOLOGY. International Journal of Technology Assessment in Health Care, 2015, 31, 347-354.	0.5	5
34	Medicare's Interventions Coverage: The Authors Reply. Health Affairs, 2015, 34, 1066-1066.	5.2	0
35	Medicare's use of cost-effectiveness analysis for prevention (but not for treatment). Health Policy, 2015, 119, 156-163.	3.0	19
36	Medicare Is Scrutinizing Evidence More Tightly For National Coverage Determinations. Health Affairs, 2015, 34, 253-260.	5.2	28

#	ARTICLE	IF	CITATIONS
37	The lag from FDA approval to published cost-utility evidence. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 399-402.	1.4	8
38	Private Payers Disagree With Medicare Over Medical Device Coverage About Half The Time. <i>Health Affairs</i> , 2015, 34, 1376-1382.	5.2	33
39	An Assessment of the Methodological Quality of Published Network Meta-Analyses: A Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0121715.	2.5	28
40	Do Changes in Drug Coverage Policy Point to an Increased Role for Cost-Effectiveness Analysis in the USA?. <i>Pharmacoeconomics</i> , 2014, 32, 729-733.	3.3	8
41	Despite High Costs, Specialty Drugs May Offer Value For Money Comparable To That Of Traditional Drugs. <i>Health Affairs</i> , 2014, 33, 1751-1760.	5.2	22
42	Potential role of network meta-analysis in value-based insurance design. <i>American Journal of Managed Care</i> , 2014, 20, 641-8.	1.1	1
43	Illustrating Potential Efficiency Gains from Using Cost-Effectiveness Evidence to Reallocate Medicare Expenditures. <i>Value in Health</i> , 2013, 16, 629-638.	0.3	19
44	What can we learn from the U.S. expanded end-stage renal disease bundle?. <i>Health Policy</i> , 2013, 110, 164-171.	3.0	28
45	Medicare Covers The Majority Of FDA-Approved Devices And Part B Drugs, But Restrictions And Discrepancies Remain. <i>Health Affairs</i> , 2013, 32, 1109-1115.	5.2	25
46	Therapies For Advanced Cancers Pose A Special Challenge For Health Technology Assessment Organizations In Many Countries. <i>Health Affairs</i> , 2012, 31, 700-708.	5.2	28
47	Medicare's Enduring Struggle to Define "Reasonable and Necessary" Care. <i>New England Journal of Medicine</i> , 2012, 367, 1775-1777.	27.0	49
48	Factors Predicting Medicare National Coverage. <i>Medical Care</i> , 2012, 50, 249-256.	2.4	29
49	Medicare's National Coverage Determinations in Diagnostic Radiology. <i>Academic Radiology</i> , 2012, 19, 1060-1065.	2.5	5
50	Risk-Sharing Arrangements That Link Payment For Drugs To Health Outcomes Are Proving Hard To Implement. <i>Health Affairs</i> , 2011, 30, 2329-2337.	5.2	90
51	What values do the public want their health care systems to use in evaluating technologies?. <i>European Journal of Health Economics</i> , 2011, 12, 285-288.	2.8	16
52	Listening to Provenge "What a Costly Cancer Treatment Says about Future Medicare Policy. <i>New England Journal of Medicine</i> , 2011, 364, 1687-1689.	27.0	58
53	Does Medicare Have an Implicit Cost-Effectiveness Threshold?. <i>Medical Decision Making</i> , 2010, 30, E14-E27.	2.4	52
54	Coverage of Specialty Drugs for Psoriasis and Psoriatic Arthritis by Commercial Insurance Companies. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 0, , 247553032211018.	0.7	0